Literature DB >> 23471521

Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Slava Rom1, Yuri Persidsky.   

Abstract

An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB(1), CB(2)) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB(2) activation. Development of CB(2) agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB(2) activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23471521      PMCID: PMC3663904          DOI: 10.1007/s11481-013-9445-9

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  138 in total

Review 1.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

2.  Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid.

Authors:  Ana María Ronco; Miguel Llanos; Daniela Tamayo; Sandra Hirsch
Journal:  Pharmacology       Date:  2006-11-16       Impact factor: 2.547

3.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

Review 4.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

5.  Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands.

Authors:  Q-R Liu; C-H Pan; A Hishimoto; C-Y Li; Z-X Xi; A Llorente-Berzal; M-P Viveros; H Ishiguro; T Arinami; E S Onaivi; G R Uhl
Journal:  Genes Brain Behav       Date:  2009-06-03       Impact factor: 3.449

6.  Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists.

Authors:  John W Huffman; Gulay Zengin; Ming-Jung Wu; Jianzhong Lu; George Hynd; Kristen Bushell; Alicia L S Thompson; Simon Bushell; Cindy Tartal; Dow P Hurst; Patricia H Reggio; Dana E Selley; Michael P Cassidy; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2005-01-03       Impact factor: 3.641

7.  A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.

Authors:  Natalya M Kogan; Michael Schlesinger; Maximilian Peters; Gergana Marincheva; Ronen Beeri; Raphael Mechoulam
Journal:  J Pharmacol Exp Ther       Date:  2007-05-03       Impact factor: 4.030

8.  Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1.

Authors:  W Zhu; H Friedman; T W Klein
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

Review 9.  Endocannabinoids in the retina: from marijuana to neuroprotection.

Authors:  Stephen Yazulla
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  80 in total

1.  Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic Potentials.

Authors:  Madhavan P Nair; Gloria Figueroa; Gianna Casteleiro; Karla Muñoz; Marisela Agudelo
Journal:  J Alcohol Drug Depend       Date:  2015-01-23

2.  Marijuana use and viral suppression in persons receiving medical care for HIV-infection.

Authors:  Chukwuemeka N Okafor; Zhi Zhou; Larry E Burrell; Natalie E Kelso; Nicole E Whitehead; Jeffery S Harman; Christa L Cook; Robert L Cook
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-11       Impact factor: 3.829

3.  Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin.

Authors:  Qiang Wei; Li Liu; Zhe Cong; Xiaoxian Wu; Hui Wang; Chuan Qin; Patricia Molina; Zhiwei Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-25       Impact factor: 4.147

Review 4.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

5.  Neurocognitive SuperAging in Older Adults Living With HIV: Demographic, Neuromedical and Everyday Functioning Correlates.

Authors:  Rowan Saloner; Laura M Campbell; Vanessa Serrano; Jessica L Montoya; Elizabeth Pasipanodya; Emily W Paolillo; Donald Franklin; Ronald J Ellis; Scott L Letendre; Ann C Collier; David B Clifford; Benjamin B Gelman; Christina M Marra; J Allen McCutchan; Susan Morgello; Ned Sacktor; Dilip V Jeste; Igor Grant; Robert K Heaton; David J Moore
Journal:  J Int Neuropsychol Soc       Date:  2019-03-20       Impact factor: 2.892

6.  Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies.

Authors:  Tarek Taha; David Meiri; Samira Talhamy; Mira Wollner; Avivit Peer; Gil Bar-Sela
Journal:  Oncologist       Date:  2019-01-22

Review 7.  Brain cannabinoid receptor 2: expression, function and modulation.

Authors:  De-Jie Chen; Ming Gao; Fen-Fei Gao; Quan-Xi Su; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2017-01-09       Impact factor: 6.150

8.  Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse.

Authors:  Daniela Muhl; Markus Kathmann; Carolin Hoyer; Laura Kranaster; Martin Hellmich; Christoph W Gerth; Johannes Faulhaber; Eberhard Schlicker; F Markus Leweke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-02       Impact factor: 3.000

Review 9.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

10.  Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition.

Authors:  Jaesuk Yun; Kyung Sik Yoon; Tac-Hyung Lee; Hyunjin Lee; Sun Mi Gu; Yun Jeong Song; Hye Jin Cha; Kyoung Moon Han; Hyewon Seo; Jisoon Shin; Hye-Kyung Park; Hyung Soo Kim; Young-Hoon Kim
Journal:  Toxicol Res (Camb)       Date:  2016-09-07       Impact factor: 3.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.